ClinicalTrials.Veeva

Menu

Beta-alanine Supplementation and Its Effects on Performance, Muscle Carnosine Content and Safety in Athletes With Spinal-cord Injury

U

University of Sao Paulo

Status

Unknown

Conditions

Spinal Cord Injuries

Treatments

Dietary Supplement: Dextrose
Dietary Supplement: Beta-alanine

Study type

Interventional

Funder types

Other

Identifiers

NCT02604927
B-Alanine Paraplegic Athletes

Details and patient eligibility

About

Paralympians competing in wheelchair sports may experience a very high glycolytic demand (and therefore acidotic environment) in their upper-body muscles, particularly in high-intensity disciplines. Previous studies from our group have shown that upper-body exercise is very sensitive to the ergogenic effects of β-alanine supplementation and to other nutritional supplements capable of increasing buffering capacity. In line with this, have shown that upper-body muscle groups benefit more from artificially induced alkalosis than lower-body muscle groups. Although β-alanine appears to be an interesting and potential ergogenic supplement for paralympians, no study to date has assessed its potential in wheelchair athletes.In this study, we will evaluate the effects of β-alanine supplementation on upper-body performance in wheelchair athletes.

Enrollment

20 estimated patients

Sex

Male

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Paralympian training for any exercise modality for at least one year;
  • A weekly training volume of 6 hours or more;
  • Have a spinal cord injury accompanied by loss of motor function in the lower limbs for at least one year;
  • Available for carrying out the experimental procedures.

Exclusion criteria

  • Use of creatine or beta-alanine for at least 3 and 6 months before the trial;
  • Cardiovascular or respiratory disease;
  • Clinical condition that result in malabsorption of nutrients;
  • Any other medical condition that prevents the realization of experimental procedures.

Trial design

20 participants in 2 patient groups, including a placebo group

Placebo
Placebo Comparator group
Description:
800 mg of dextrose, four times per day, during 28 days.
Treatment:
Dietary Supplement: Dextrose
Beta-alanine
Experimental group
Description:
800 mg of beta-alanine, four times per day, during 28 days.
Treatment:
Dietary Supplement: Beta-alanine

Trial contacts and locations

1

Loading...

Central trial contact

Guilherme Artioli, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems